Nanomed is participating today in the 2nd AGP&DTx Summit Forum at the Hilton Shenzhen Shekou Nanhai Hotel in Shenzhen. This prestigious event, organized by the National Innovation Center for High-Performance Medical Devices and the China Dynamic Glucose Atlas and Digital Therapeutics R&D Center (China AGP&DTx R&D Center), serves as a key platform for the exchange of knowledge and innovations in the field of digital diabetes management.
The forum, titled "Focusing on the Combination of AGP and Digital Intelligent Management of Diabetes and Discussing Its Application in the Medical Field," gathers leading endocrinology experts from China and abroad, including Prof. Dr. Slađana Todorović from Serbia, as well as experts from Slovenia, Australia, Turkey, and Algeria. Led by Professor Ji Linong, the initiator of the China AGP&DTx R&D Center and a professor at Peking University People's Hospital, the forum will explore the application of CGM technology, AGP, and digital intelligent diabetes management.
Given that China has the largest number of diabetic patients in the world, with over 140 million patients, along with a low control rate and high risk of complications, personalized diabetes management and improving management efficiency are key challenges. The development of big data, artificial intelligence (AI), and digital therapeutics brings innovations to this field, enabling the digitalization and intelligentization of diabetes diagnosis and treatment.
During the forum, domestic and international experts will conduct special interviews on the topic of "digital intelligence of diabetes" and discuss important topics such as AGP consensus, CGM data for 70,000 Chinese patients, the artificial pancreas system, and digital intelligent health management.
